- Published at
- by investing.com
neutral
neutral
Kala Bio executive sells shares worth over $22,000 By Investing.com
Kala Bio executive sells shares worth over $22,000
News for Kala Pharmaceuticals, Inc. (KALA)
- Published at
- by investing.com
neutralneutralKala Bio's chief business officer sells shares worth $24,500 By Investing.com
Kala Bio's chief business officer sells shares worth $24,500- Published at
- by investing.com
neutralneutralKala stock PT lowered by H.C. Wainwright amid bigger-than-expected net loss By Investing.com
Kala stock PT lowered by H.C. Wainwright amid bigger-than-expected net loss- Published at
- by seekingalpha.com
neutralneutralKala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44 (NASDAQ:KALA)
Kala Pharmaceuticals reports Q4 GAAP EPS of -$3.18, beating expectations by $0.44.- Published at
- by globenewswire.com
mixedmixedGlobal Ophthalmic Drugs Market Size is Estimated to Reach USD 62.55 billion by 2030, Growing at a CAGR of 7.4%: Straits Research
The market has been driven by the increasing prevalence of retinal illnesses worldwide and the demand for effective and economical treatment options. For...- Published at
- by globenewswire.com
mixedmixedDry Eye Syndrome Market Size Worth USD 10.55 Billion in 2032 | Emergen Research
Rising demand for effective treatments, and strong R&D investments to support pipeline candidates are expected to drive Dry Eye Syndrome market growth....- Published at
- by globenewswire.com
neutralneutral- Published at
- by prnewswire.com
mixedmixedGlobal $500+ Mn Neurotrophic Keratitis Markets, 2023-2028: Empowering Vision Health - Neurotrophic Keratitis Market on the Rise
/PRNewswire/ -- The "Global Neurotrophic Keratitis Market (2023-2028) by Route of Administration, Distribution Channel, and Geography, Competitive Analysis,...- Published at
- by globenewswire.com
mixedmixedKALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio,...- Published at
- by seekingalpha.com
positivepositiveKala Pharmaceuticals' KPI-012: Novel Orphan Drug Therapy For PCED
Kala has a promising drug, KPI-012, in its pipeline for treating Persistent Corneal Epithelial Defect (PCED). Read why I give a hold rating to KALA stock.- Published at
- by benzinga.com
positivepositiveKala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kala Pharmaceuticals (NASDAQ:KALA)
ARLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options and restricted stock units (RSUs) to new employees as- Published at
- by globenewswire.com
positivepositiveKala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory...- Published at
- by globenewswire.com
positivepositiveKala Pharmaceuticals to Present at the Jefferies Healthcare Conference
ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the...- Published at
- by rttnews.com
neutralneutralKala Pharmaceuticals Adds 6% In Morning Trade
Shares of Kala Pharmaceuticals, Inc. (KALA) are rising more than 6% Friday morning at $16.43..- Published at
- by marketscreener.com
positivepositiveKala Pharmaceuticals Shares Rise Nearly 5% After FDA Fast Track Designation
By Dia Gill Kala Pharmaceuticals Inc. shares climbed 4.6% to $17.83 during Wednesday morning trading after the U.S. Food and Drug Administration gave Fast Track designation to Kala's human... | April 12, 2023- Published at
- by rttnews.com
mixedmixed- Published at
- by rttnews.com
mixedmixed- Published at
- by investing.com
mixedmixedU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.17% By Investing.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.17%OBSVN.MXOBSVOBSN.SWMCAEUMCAERMCAEMCACUMCACRKALAILU.DEILMN.MXILMNI1LM34.SADOW1.MXD1OW34.SAAPC.DEALGN.MXALGNAAPLD.BAAAPLCL.SNAAPLC.BAAAPL.SNAAPL.NEAAPL.MXAAPL.BAAAPLA1LG34.SA0JQ2.L0J8Z.L0HCK.LVZ.SNVZ.MXVZ.BAVZVERZ34.SADOWBAC.DE2OY.DEVERUSECOPRAXLUMN.MXLUMNKOD.BAKOCL.SNKOC.BAHRLHO7.DECOSTCL.SNCOSTBACL.SN0J5Z.L0HVP.L- Published at
- by seekingalpha.com
positivepositiveAldeyra Therapeutics: Catalyst Rich 2023 Holds Promise But Also Risk (NASDAQ:ALDX)
Aldeyra Therapeutics is a mid-cap biotech with an intriguing approach and pipeline. Read why I'll likely be watching ALDX stock from the sidelines.- Published at
- by investing.com
mixedmixedU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.80% By Investing.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.80%